We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics


Designs, develops, manufactures and markets in vitro diagnostics systems used in clinical and industrial applications read more Featured Products: More products

Download Mobile App

Biomérieux Molecular Tests Amplify and Detect SARS-CoV-2 Omicron Variant

By LabMedica International staff writers
Posted on 07 Dec 2021
Print article
Image: BioFire Respiratory 2.1 (RP2.1) Panel (Photo courtesy of bioMérieux)
Image: BioFire Respiratory 2.1 (RP2.1) Panel (Photo courtesy of bioMérieux)

bioMérieux (Marcy-l'Étoile, France) has performed an analysis that confirms its BIOFIRE and ARGENE molecular tests efficiently amplify and detect SARS-CoV-2 infection with Omicron variant with an unchanged performance.

Since the beginning of the pandemic bioMérieux's research and development teams have closely monitored the emergence of each variants of concern and systematically conducted in-depth in silico internal analyses. From the early onset of the pandemic, bioMérieux has been committed to meeting the COVID-19 public health challenge. The company keeps following the evolution of the pandemic and the scientific knowledge about the virus with the utmost attention and continuously works to anticipate developments in diagnostic tests that will meet future public health needs.

The first Omicron (B.1.1.529) case was reported to the World Health Organization (WHO) on November 24. Just two days later, the WHO designated the variant a Variant of Concern (VOC), based on its unusually large number of mutations and early evidence of its spread. Despite a series of rapidly implemented travel bans, it has now been reported in Africa, many European countries, and a few in Asian countries.

bioMérieux’s analyses allow it to confirm that to date, the company’s BIOFIRE and ARGENE molecular tests efficiently amplify and detect SARS-CoV-2 infection with Omicron variant with an unchanged performance.

Related Links:

Gold Supplier
SARS-CoV-2 (ORF1a, N, RdRp) Real-Time RT-PCR Test
DiaPlexQ SARS-CoV-2 (ORF1a, N, RdRp)
POC Clinical Chemistry Analyzer
Automatic Nucleic Acid Purification System
GenePure Pro
Integrated Urinalysis Chemistry Analyzer

Print article
IIR Middle East


Molecular Diagnostics

view channel

Point-of-Care Lateral Flow Test Detects Bladder Cancer Using Urine Sample within Minutes

A breakthrough diagnostics platform uses a multiplexed lateral flow assay that detects 10 bladder cancer biomarkers from a urine sample in either laboratory or point-of-care settings. SCIENION (Berlin,... Read more


view channel
Image: Bone marrow aspirate from a patient with Acute Myeloid Leukemia: Blasts are the predominant population and have a high nuclear to cytoplasmic ratio and generally lack granules. (Photo courtesy of Professor Peter G. Maslak, MD)

Cord Blood and Matched Related Donor Transplantation Compared in Acute Myeloid Leukemia

The prognosis of primary refractory and relapsed acute myeloid leukemia is poor, with a five-year overall survival of less than 10%. Allogeneic hematopoietic stem cell transplantation (HSCT) is the only... Read more


view channel

Global Immunofluorescence Assay (IFA) Market to Surpass USD 4 Billion by 2028 Due to Growing Burden of Infectious Diseases

The global immunofluorescence assay (IFA) market is expected to reach USD 4.01 billion by 2028, driven by the increasing global healthcare burden of chronic and infectious diseases, rising application... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.